We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-2.1%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.12B
AUM Growth
-$506M
(-9%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-25.88%
Top 10 Holdings %
Top 10 Hldgs %
36.5%
Holding
171
New
28
Increased
20
Reduced
18
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVL
Nuvalent
NUVL
|
+$561M |
| 2 |
GeneDx Holdings
WGS
|
+$144M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$39.4M |
| 4 |
Glaukos
GKOS
|
+$34.3M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$31.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$54.4M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$54.1M |
| 3 |
QuidelOrtho
QDEL
|
+$52.4M |
| 4 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$45.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$42.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.12% |
| 2 | Financials | 1.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVL
1
DELISTED
Nuvalent
NUVL
| $436M | 8.51% |
+19,341,024
| New | +$561M |
|
2
Viatris
VTRS
$20.1B
| $255M | 4.98% |
18,824,000
| – | – |
|
3
AdaptHealth
AHCO
$1.49B
| $189M | 3.68% |
8,103,792
+750,000
| +10% | +$18.1M |
|
|
CMAX
4
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $162M | 3.16% |
559,292
| – | – |
|
|
5
Neurocrine Biosciences
NBIX
$17.2B
| $110M | 2.14% |
1,142,415
+417,415
| +58% | +$39.4M |
|
6
Organogenesis Holdings
ORGO
$337M
| $106M | 2.07% |
7,462,543
+240,416
| +3% | +$3.73M |
|
|
7
GeneDx Holdings
WGS
$1.88B
| $105M | 2.05% |
+419,651
| New | +$144M |
|
|
OMIC
8
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $102M | 1.99% |
303,734
| – | – |
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $79M | 1.54% |
4,863,725
-903,684
| -16% | -$9.83M |
|
10
Pulmonx
LUNG
$59.1M
| $73M | 1.43% |
2,029,887
+229,000
| +13% | +$9.01M |
|
11
Larimar Therapeutics
LRMR
$384M
| $67.2M | 1.31% |
5,830,249
| – | – |
|
12
Mirum Pharmaceuticals
MIRM
$7.25B
| $65.4M | 1.28% |
3,282,912
-166,000
| -5% | -$2.7M |
|
13
Edgewise Therapeutics
EWTX
$4.28B
| $65.3M | 1.27% |
3,933,137
| – | – |
|
14
Molina Healthcare
MOH
$11.7B
| $62.9M | 1.23% |
231,776
| – | – |
|
15
Centene
CNC
$32.8B
| $62.5M | 1.22% |
1,003,800
+8,800
| +0.9% | +$588K |
|
16
Cytokinetics
CYTK
$10.9B
| $54.9M | 1.07% |
1,536,758
+298,675
| +24% | +$8.79M |
|
|
SILK
17
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $54.5M | 1.06% |
990,251
-148,274
| -13% | -$7.76M |
|
18
Pacira BioSciences
PCRX
$1.01B
| $54.2M | 1.06% |
967,236
-179,764
| -16% | -$10.4M |
|
|
APR
19
DELISTED
Apria, Inc. Common Stock
APR
| $52.7M | 1.03% |
1,417,700
-155,192
| -10% | -$5.11M |
|
20
The Oncology Institute
TOI
$535M
| $49.7M | 0.97% |
5,000,000
| – | – |
|
21
Alphatec Holdings
ATEC
$1.31B
| $43.8M | 0.86% |
3,594,829
+192,445
| +6% | +$2.68M |
|
22
Kura Oncology
KURA
$964M
| $43.4M | 0.85% |
2,315,417
+521,417
| +29% | +$9.83M |
|
23
Revolution Medicines
RVMD
$39.6B
| $43.1M | 0.84% |
1,565,712
| – | – |
|
|
DAWN
24
DELISTED
Day One Biopharmaceuticals
DAWN
| $40.6M | 0.79% |
1,710,730
+891,750
| +109% | +$21.4M |
|
|
VIVO
25
DELISTED
Meridian Bioscience Inc
VIVO
| $39.7M | 0.77% |
2,063,083
+638,809
| +45% | +$12.7M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2021 Portfolio in Review
As of Q3 2021, Deerfield Management held 171 positions worth $5.12B, down 9% from $5.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Deerfield Management withdrew a net $1.33B in Q3 2021, closing 38 positions and reducing 18 holdings. Its most notable exit was Zimmer Biomet, an estimated $54.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 68% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Nuvalent worth $436M.
- Deerfield Management's largest Q3 2021 buy was Nuvalent: 19,341,024 shares worth $436M.
- Deerfield Management added most to Neurocrine Biosciences in Q3 2021, an estimated $39.4M increase.
- Deerfield Management's biggest Q3 2021 reduction was BioCryst Pharmaceuticals, cutting an estimated $41M.
- Deerfield Management fully exited Zimmer Biomet in Q3 2021, selling an estimated $54.4M.
- Deerfield Management's ten largest holdings make up 37% of its $5.12B portfolio in Q3 2021.
- Deerfield Management opened 28 new positions and closed 38 in Q3 2021.
- Deerfield Management's portfolio value fell 9% quarter-over-quarter to $5.12B.
Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.